LPL Financial LLC Purchases 42,232 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

LPL Financial LLC grew its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 39.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 149,726 shares of the company's stock after buying an additional 42,232 shares during the quarter. LPL Financial LLC owned approximately 0.18% of CRISPR Therapeutics worth $5,893,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in CRSP. Highline Wealth Partners LLC purchased a new stake in CRISPR Therapeutics in the fourth quarter worth $39,000. Western Pacific Wealth Management LP lifted its position in shares of CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock worth $39,000 after purchasing an additional 500 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of CRISPR Therapeutics during the 3rd quarter valued at about $40,000. Spire Wealth Management increased its position in shares of CRISPR Therapeutics by 303.7% during the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company's stock valued at $78,000 after buying an additional 1,482 shares during the period. Finally, MCF Advisors LLC purchased a new stake in CRISPR Therapeutics in the fourth quarter worth about $80,000. 69.20% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Samarth Kulkarni sold 9,973 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $423,054.66. Following the transaction, the chief executive officer now owns 180,890 shares of the company's stock, valued at approximately $7,673,353.80. This trade represents a 5.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Julianne Bruno sold 1,198 shares of CRISPR Therapeutics stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the transaction, the chief operating officer now owns 8,263 shares in the company, valued at $350,516.46. This represents a 12.66 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 32,381 shares of company stock valued at $1,608,243 in the last ninety days. 4.10% of the stock is currently owned by company insiders.

Remove Ads

CRISPR Therapeutics Trading Up 14.7 %

NASDAQ:CRSP traded up $5.04 during mid-day trading on Friday, reaching $39.30. The company's stock had a trading volume of 3,645,107 shares, compared to its average volume of 1,622,765. The stock has a market cap of $3.37 billion, a P/E ratio of -8.99 and a beta of 1.85. The firm's fifty day moving average price is $41.14 and its two-hundred day moving average price is $44.03. CRISPR Therapeutics AG has a 12-month low of $30.04 and a 12-month high of $67.88.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. HC Wainwright reissued a "buy" rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. TD Cowen upgraded CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 price objective for the company in a report on Wednesday, February 12th. Evercore ISI upgraded shares of CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and boosted their target price for the company from $60.00 to $99.00 in a report on Friday, February 14th. Chardan Capital decreased their price target on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. Finally, Royal Bank of Canada lowered their price target on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating for the company in a research report on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $73.11.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.